Antithrombotic therapy. Rationale and application.
Arterial thrombosis and venous thrombosis differ in pathogenesis, morphology, and response to antithrombotic therapy. Antiplatelet therapy usually is aimed at arterial thrombi, in whose formation platelet-mediated reactions predominate, while anticoagulant therapy is effective against venous thrombi, in whose formation coagulation predominates.
D000925:Anticoagulants / Q000627:therapeutic use*; D001158:Arteries / Q000293:injuries; D001161:Arteriosclerosis / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000096:biosynthesis; D004176:Dipyridamole / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy* / Q000209:etiology; D013927:Thrombosis / Q000188:drug therapy* / Q000209:etiology; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014680:Veins / Q000293:injuries; D014859:Warfarin / Q000378:metabolism
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D014859:Warfarin; D004176:Dipyridamole; D014568:Urokinase-Type Plasminogen Activator; D001241:Aspirin; D013442:Sulfinpyrazone